Clinical Trial Update: Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A pilot Phase 1/2 study evaluating safety and efficacy of NiCord and UNM CBU in patients with various hematologic malignancies has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Hodgkin Disease
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• NiCord (omidubicel)
• UNM CBU (UNM CBU)

Snippet

Sponsor: Gamida Cell ltd | Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-02-26